JBJyoti Batra

Jyoti Batra

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jyoti Batra has a total of 477 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Coronavirus protein interaction mapping in bat and human cells reveals network rewiring governing immune evasion and zoonotic potential

    by Jyoti Batra, Magdalena Rutkowska, Yuan Zhou, Chengjin Ye, Rithika Adavikolanu, Janet M. Young, Durga Anand, Sooraj Verma, Haripriya Parthasarathy, Martin Gordon, et al.


  • Open Access

    Coupled equilibria of dimerization and lipid binding modulate SARS Cov 2 Orf9b interactions and interferon response

    by Cj San Felipe, Jyoti Batra, Monita Muralidharan, Shivali Malpotra, Durga Anand, Rachel Bauer, Kliment A Verba, Danielle L Swaney, Nevan J Krogan, Michael Grabe, et al.

    Open Reading Frame 9b (Orf9b), an accessory protein of SARS-CoV and –2, is involved in innate immune suppression through its binding to the mitochondrial receptor Translocase of Outer Membrane 70 (Tom70). Previous structural studies of Orf9b in isolation revealed a β-sheet-rich homodimer; however, structures of Orf9b in complex with Tom70 revealed a monomeric helical fold. Here, we developed a biophysical model that quantifies how Orf9b switches between these conformations and binds to Tom70, a requirement for suppressing the type 1 interferon response. We used this model to characterize the effect of lipid binding and mutations in variants of concern to the Orf9b:Tom70 equilibrium. We found that the binding of a lipid to the Orf9b homodimer biases the Orf9b monomer:dimer equilibrium towards the dimer by reducing the dimer dissociation rate ~100 fold. We also found that mutations in variants of concern can alter different microscopic rate constants without significantly affecting binding to Tom70. Together, our results highlight how perturbations to different steps in these coupled equilibria can affect the apparent affinity of Orf9b to Tom70, with potential downstream implications for interferon signaling in coronavirus infection.


  • Open Access

    Coronavirus protein interaction mapping in bat and human cells identifies molecular and genetic switches for immune evasion and replication

    by Jyoti Batra, Magdalena Rutkowska, Yuan Zhou, Chengjin Ye, Rithika Adavikolanu, Janet M. Young, Durga Anand, Sooraj Verma, Martin Gordon, Shivali Malpotra, et al.

    Summary: Coronaviruses, including SARS-CoV-2, can cause severe disease in humans, whereas reservoir hosts like Rhinolophus bats remain asymptomatic. To investigate how host-specific protein-protein interactions (PPIs) influence infection, we generated comparative PPI maps for SARS-CoV-2 and its bat-origin relative RaTG13 using affinity purification-mass spectrometry (AP-MS) in human and Rhinolophus ferrumequinum (RFe) bat cells. This approach identified both conserved and virus- and host-specific interactions that regulate infection dynamics. Notably, SARS-CoV-2 required a non-synonymous mutation in nucleocapsid to replicate in bat cells expressing human ACE2 and TMPRSS2. Analysis of the viral protein Orf9b revealed differential interactions with mitochondrial proteins Tom70 and MTARC2. A single residue difference in Orf9b between SARS-CoV-2 and RaTG13 functions as a molecular switch, weakening Tom70 binding and immune evasion in human cells while enhancing interaction with the bat-specific restriction factor MTARC2. These findings demonstrate how a single-residue substitution can reshape virus-host interactions and contribute to immune evasion and host adaptation.


  • Open Access

    Table S1 from The Landscape of Human Cancer Proteins Targeted by SARS-CoV-2

    by Beril Tutuncuoglu, Merve Cakir, Jyoti Batra, Mehdi Bouhaddou, Manon Eckhardt, David E. Gordon, Nevan J. Krogan

    Cancer drugs targeting the identified virus-host protein-protein interactions of SARS-CoV-2

  • Open Access

    Table S1 from The Landscape of Human Cancer Proteins Targeted by SARS-CoV-2

    by Beril Tutuncuoglu, Merve Cakir, Jyoti Batra, Mehdi Bouhaddou, Manon Eckhardt, David E. Gordon, Nevan J. Krogan

    Cancer drugs targeting the identified virus-host protein-protein interactions of SARS-CoV-2

  • Open Access

    Antimicrobial Resistance: Mechanisms, Screening Techniques and Biosensors

    by Vandana Singh, Ekta Kasana, Jyoti Batra, Harsh Sable, Rahul Saxena

    Antimicrobial resistance is one of the greatest dangers to public health on a worldwide scale. Even though the evolution of resistant microbes is a naturally occurring phenomenon, the excessive or improper use of antimicrobial agents has significantly impacted resistance evolution. Effective treatment techniques can be guided by rapid diagnostic tests of these resistance to detect drug-resistant microorganisms quickly, assess antimicrobial susceptibility, and bacterial infections from differentiate viral. In addition, quick diagnostic test could assist epidemiological surveillance by monitoring developing resistance to pathogenic pathogens and their transmission. Methods for AMR detection, and surveillance, includes Microscopy, PCR, DNA microarray, matrix-assisted laser desorption,Pyrosequencing, NAAT, whole genome sequencing, Immuno detection, spectroscopy, FTIR, Biosensor, and microfluidics technology. The AMR turmoil necessitates a concerted effort from researchers to improve the current approaches for treatment and diagnosis by developing novel techniques that circumvent the limitations and drawbacks of the best alternatives and conventional AST methods. This review mainly summarizes the different emerging diagnostic techniques used to detect antibiotic resistance and the mechanism of drug resistance. These emerging diagnostic strategies might improve medication development strategies and the surveillance of resistance evolution.


  • Open Access

    Evolution of enhanced innate immune evasion by the SARS-CoV-2 B.1.1.7 UK variant

    by Lucy G Thorne, Mehdi Bouhaddou, Ann-Kathrin Reuschl, Lorena Zuliani-Alvarez, Ben Polacco, Adrian Pelin, Jyoti Batra, Matthew V.X. Whelan, Manisha Ummadi, Ajda Rojc, et al.

    Emergence of SARS-CoV-2 variants, including the globally successful B.1.1.7 lineage, suggests viral adaptations to host selective pressures resulting in more efficient transmission. Although much effort has focused on Spike adaptation for viral entry and adaptive immune escape, B.1.1.7 mutations outside Spike likely contribute to enhance transmission. Here we used unbiased abundance proteomics, phosphoproteomics, mRNA sequencing and viral replication assays to show that B.1.1.7 isolates more effectively suppress host innate immune responses in airway epithelial cells. We found that B.1.1.7 isolates have dramatically increased subgenomic RNA and protein levels of Orf9b and Orf6, both known innate immune antagonists. Expression of Orf9b alone suppressed the innate immune response through interaction with TOM70, a mitochondrial protein required for RNA sensing adaptor MAVS activation, and Orf9b binding and activity was regulated via phosphorylation. We conclude that B.1.1.7 has evolved beyond the Spike coding region to more effectively antagonise host innate immune responses through upregulation of specific subgenomic RNA synthesis and increased protein expression of key innate immune antagonists. We propose that more effective innate immune antagonism increases the likelihood of successful B.1.1.7 transmission, and may increase in vivo replication and duration of infection.


  • Top Cited Papers
    Open Access

    Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A

    by Kris M. White, Romel Rosales, Soner Yildiz, Thomas Kehrer, Lisa Miorin, Elena Moreno, Sonia Jangra, Melissa B. Uccellini, Raveen Rathnasinghe, Lynda Coughlan, et al.

    Hurting the virus by targeting the host: Many host proteins play a role in the life cycle of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and some are required for viral replication and translation. There are efforts toward finding drugs that target viral proteins, but a complementary approach is to target these required host proteins. White et al. explored the antiviral activity of the cyclic depsipeptide drug plitidepsin, which targets the hosts cell's translational machinery (see the Perspective by Wong and Damania). The authors show that in cells, the drug is substantially more potent than remdesivir against SARS-CoV-2, with limited cellular toxicity. Prophylactic treatment protected mice against SARS-CoV-2 infection, so further investigation of plitidepsin as a therapeutic is warranted. Science , this issue p. 926 ; see also p. 884


  • Top Cited Papers
    Open Access

    Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms

    by David E. Gordon, Joseph Hiatt, Mehdi Bouhaddou, Veronica V. Rezelj, Svenja Ulferts, Hannes Braberg, Alexander S. Jureka, Kirsten Obernier, Jeffrey Z. Guo, Jyoti Batra, et al.

    How lethal coronaviruses engage hosts: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is closely related to the deadly coronaviruses SARS-CoV-1 and Middle East respiratory syndrome coronavirus (MERS-CoV). Considerable efforts are focused on developing treatments, and therapies that work across coronaviruses would be particularly valuable. Shedding light on the host factors hijacked by the viruses, Gordon et al. mapped the interactions between viral and human proteins for SARS-CoV-2, SARS-CoV-1, and MERS-CoV; analyzed the localization of viral proteins in human cells; and used genetic screening to identify host factors that either enhance or inhibit viral infection. For a subset of the interactions essential for the virus life cycle, the authors determined the cryo–electron microscopy structures and mined patient data to understand how targeting host factors may be relevant to clinical outcomes. Science , this issue p. eabe9403


  • Open Access

    A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing

    by David E. Gordon, Gwendolyn M. Jang, Mehdi Bouhaddou, Jiewei Xu, Kirsten Obernier, Matthew J. O’meara, Jeffrey Z. Guo, Danielle L. Swaney, Tia A. Tummino, Ruth Huettenhain, et al.

    An outbreak of the novel coronavirus SARS-CoV-2, the causative agent of COVID-19 respiratory disease, has infected over 290,000 people since the end of 2019, killed over 12,000, and caused worldwide social and economic disruption 1,2 . There are currently no antiviral drugs with proven efficacy nor are there vaccines for its prevention. Unfortunately, the scientific community has little knowledge of the molecular details of SARS-CoV-2 infection. To illuminate this, we cloned, tagged and expressed 26 of the 29 viral proteins in human cells and identified the human proteins physically associated with each using affinity-purification mass spectrometry (AP-MS), which identified 332 high confidence SARS-CoV-2-human protein-protein interactions (PPIs). Among these, we identify 67 druggable human proteins or host factors targeted by 69 existing FDA-approved drugs, drugs in clinical trials and/or preclinical compounds, that we are currently evaluating for efficacy in live SARS-CoV-2 infection assays. The identification of host dependency factors mediating virus infection may provide key insights into effective molecular targets for developing broadly acting antiviral therapeutics against SARS-CoV-2 and other deadly coronavirus strains.